beks-AIR-oh-teen
High Alert
Contraindicated in:
Pregnancy
;Use Cautiously in:
Women of reproductive potential and men with female partners of reproductive potential
;Oral
CV: peripheral edema
Derm: dry skin, rash, alopecia, exfoliative dermatitis, photosensitivity
EENT: new/worsening cataracts
Endo: hyperlipidemia, hypothyroidism, hypercholesterolemia
GI: abdominal pain, nausea, ↑liver enzymes, anorexia, diarrhea, PANCREATITIS, vomiting
Hemat: anemia, leukopenia
Neuro: headache, weakness, insomnia
Misc: flu-like syndrome
Topical
CV: edema
Derm: pruritus, skin disorder, rash
Endo: hyperlipidemia
Hemat: leukopenia
Misc: lymphadenopathy
Drug-drug:
Absorption: Well absorbed following oral administration; absorption is enhanced by a fat-containing meal. Some systemic absorption follows topical application.
Distribution: Unknown.
Protein Binding: >99%.
Half-Life: 7 hr.
(improvement in lesions)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO, Top | within 4 wk‡ | unknown | unknown |
‡Some responses took longer.
May cause fetal harm. Pregnancy tests will be taken before starting and monthly during therapy. Effective contraception must be used 1 mo before beginning therapy, during, and 1 mo following therapy. Two forms of contraception are recommended, with at least one being condom, diaphragm, cervical cap, IUD, or spermicide. Patients should not breastfeed during therapy. Male patients whose partner is pregnant or capable of becoming pregnant must use a condom during and for ≥1 mo after completion of therapy.
NDC Code